BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant

Reuters11-19

Nov 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:

ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE
ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS

Source text: ID:nGNX9qVV6k

Further company coverage: ELDN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584163966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584163966","market":"us","top_or_hot":-1,"title":"BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant </title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span>Eledon Pharmaceuticals Inc <span>ELDN.O</span>:</p><ul><li><p>ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE</p></li><li><p>ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS</p></li></ul><p>Source text: <span>ID:nGNX9qVV6k</span></p><p>Further company coverage: <span>ELDN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant </title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span>Eledon Pharmaceuticals Inc <span>ELDN.O</span>:</p><ul><li><p>ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE</p></li><li><p>ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS</p></li></ul><p>Source text: <span>ID:nGNX9qVV6k</span></p><p>Further company coverage: <span>ELDN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUABCHBNC:1","article_id":"2584163966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584163966","pubTimestamp":1763501761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant Nov 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:ELEDON RE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ELDN":"Eledon Pharmaceuticals, Inc."},"translate_title":"BRIEF-Eledon报告了首批6例以Tegoprubart作为核心免疫抑制剂治疗的1型糖尿病患者的初步数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELDN":0.9},"content_text":"BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant Nov 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINEELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTSSource text: ID:nGNX9qVV6kFurther company coverage: ELDN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584163966","isCrawlerRequest":true}